To examine B7H6 as a potential target for CAR T therapy to AML and melanoma, we thus developed two different second-generation CAR constructs composed of the extracellular domain of the NCR NKp30 and either CD28 or CD137 as costimulatory domains fused to the CD3ζ signaling moiety. This evidence concerns the gene NCR3 and melanoma.